Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Jie Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Pharmacovigilance, Hepatitis B virus, Virus Activation, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: This work was supported by grants by Fundamental Research Funds for the Central Universities, grant No. 2022ZFJH003; National Key R&D Program of China (2019YFC….
Abstract (Originalsprache)
Hepatitis B virus reactivation (HBVr) can be a serious clinical complication that has not been fully characterized in terms of the drugs associated with this adverse effect. Leveraging the expansive data available in the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases, we conducted a retrospective analysis to identify drugs significantly linked to HBVr using three disproportionality analyses. Our study identified 44 drugs associated with HBVr, of which 35 did not have warnings in their product labels. The majority of these drugs were antineoplastic and immunomodulating agents, with a tendency for early occurrence of HBVr, particularly among antineoplastic agents and systemic corticosteroids. Additionally, entecavir, tenofovir disoproxil and tenofovir alafenamide demonstrated better safety profiles in preventing HBVr. These findings enhance our understanding of the demographic characteristics of patients at risk for HBVr, the drugs that pose a high risk for HBVr, the timing of such events, and the appropriate preventive medications. This knowledge contributes to the development of better prevention and treatment strategies, ultimately optimizing patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Department of Critical Care Medicine, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang Province, China.
- Department of Infectious Diseases, ShuLan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang Province, China.
ORCID-Profile: Lanjuan Li
Förderung
- This work was supported by grants by Fundamental Research Funds for the Central Universities, grant No. 2022ZFJH003; National Key R&D Program of China (2019YFC…
Zitieren
APA
Wang, J., Jiang, H., Zhang, G., Dai, X., Gao, H., & Li, L. (2024). Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation. Journal of Medical Virology. https://doi.org/10.1002/jmv.70055
Vancouver
Wang J, Jiang H, Zhang G, Dai X, Gao H, Li L. Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation. Journal of Medical Virology. 2024. doi:10.1002/jmv.70055
BibTeX
@article{Wang2024,
author = {Wang, Jie and Jiang, He and Zhang, Guoqi and Dai, Xiahong and Gao, Hainv and Li, Lanjuan},
title = {Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70055}
}
EUVIMED